Basel, 04 December 2018 New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemia New analyses from the phase III MURANO study in previously treated chronic lymphocytic leukaemia show continued benefit from fixed-duration regimen after a median follow-up of three years Updated results from two studies in newly-diagnosed acute myeloid... Read more
Basel, 03 December 2018 Roche’s Hemlibra provided sustained bleed control in the largest pivotal study to date of children with haemophilia A with factor VIII inhibitors Nearly 77% of children receiving Hemlibra once weekly experienced zero treated bleeds Hemlibra once weekly reduced treated bleeds by 99% compared to prior bypassing agents in a prospective intra-patient... Read more
Basel, 03 December 2018 Longer-term follow-up data demonstrate sustained benefit of polatuzumab vedotin-based treatment in relapsed or refractory diffuse large B-cell lymphoma Polatuzumab vedotin in combination with MabThera/Rituxan (rituximab) plus bendamustine more than doubled overall survival, compared to MabThera/Rituxan plus bendamustine alone in the phase Ib/II GO29365 study Polatuzumab vedotin has the potential to provide... Read more
The VENTANA pan-TRK (EPR17341) Assay1 is the first assay of its type to detect tropomyosin receptor kinase (TRK) with anticipated use across multiple solid tumor types The assay is expected to provide improved data on the prevalence of TRK proteins in tumor tissue studies The significance of TRK fusion proteins is currently being investigated in various... Read more
Basel, 21 November 2018 Roche announces FDA grants Venclexta accelerated approval for people with newly-diagnosed acute myeloid leukaemia or those who are ineligible for intensive induction chemotherapy Approval based on two studies that showed durable remissions in people with newly-diagnosed acute myeloid leukaemia, who are age 75 years or older, or for those ineligible for... Read more
Basel, 01 November 2018 Phase III data showed that Venclexta/Venclyxto plus Gazyva/Gazyvaro reduced the risk of disease worsening or death in people with previously untreated chronic lymphocytic leukaemia with co-morbidities The phase III CLL14 study compared Venclexta/Venclyxto in combination with Gazyva/Gazyvaro to standard-of-care Gazyva/Gazyvaro plus chlorambucil Data will be submitted to health authorities and presented... Read more
Basel, 16 October 2018 Reminder: Invitation to Roche’s live audio webcast at the 2018 European Society for Medical Oncology (ESMO) Congress We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Monday, 22 October 2018, to discuss key data presented on the Roche Group’s oncology portfolio and pipeline during the... Read more
Partnership that grows stronger While DASA has experienced unprecedented growth and success with their integrated lab, they don’t plan on slowing down. Alessandro Veiga states, “We haven’t stopped growing. DASA has an expectation to become a global leader in diagnostic medicine throughout the world.” DASA Group’s vision is to be the best company in the... Read more
Basel, 15 October 2018 Roche launches NGS AVENIO Tumor Tissue Analysis Kits for oncology research Ready-to-use kits determine genomic characteristics of solid tumours Optimized workflow to generate results in house Software analysis allows correlation to AVENIO ctDNA NGS kits Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the global commercial launch of three new next-generation... Read more
Basel, 10 October 2018 OCREVUS (ocrelizumab) data show early initiation of treatment reduces disability progression over five years in relapsing and primary progressive multiple sclerosis People with relapsing MS (RMS) treated sooner with OCREVUS had earlier reduction in disease activity and less disability progression vs. those who switched from interferon beta-1α People with primary progressive... Read more